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Pseudomonas aeruginosa and Staphylococcus aureus are pathogens able to colonize
surfaces and form together a mixed biofilm. Dual-species biofilms are significantly
more resistant to antimicrobials than a monomicrobial community, leading to treatment
failure. Due to their rapid bactericidal activity, the self-amplification ability and the
biofilm degrading properties, bacteriophages represent a promising therapeutic option
in fighting biofilm-related infections. In this study, we investigated the effect of either
the simultaneous or staggered application of commercially available phages and
ciprofloxacin versus S. aureus/P. aeruginosa dual-species biofilms in vitro. Biofilms
were grown on porous glass beads and analyzed over time. Different techniques
such as microcalorimetry, sonication and scanning electron microscopy were combined
for the evaluation of anti-biofilm activities. Both bacterial species were susceptible to
ciprofloxacin and to phages in their planktonic form of growth. Ciprofloxacin tested
alone against biofilms required high concentration ranging from 256 to >512 mg/L
to show an inhibitory effect, whereas phages alone showed good and moderate
activity against MRSA biofilms and dual-species biofilms, respectively, but low activity
against P. aeruginosa biofilms. The combination of ciprofloxacin with phages showed
a remarkable improvement in the anti-biofilm activity of both antimicrobials with
complete eradication of dual-species biofilms after staggered exposure to Pyophage or
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Pyophage + Staphylococcal phage for 12 h followed by 1 mg/L of ciprofloxacin, a
dose achievable by intravenous or oral antibiotic administration. Our study provides
also valuable data regarding not only dosage but also an optimal time of antimicrobial
exposure, which is crucial in the implementation of combined therapies.
Keywords: Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus, biofilm-associated infection,
dual-species biofilm, antibiotic-bacteriophage combination, bacteriophages, isothermal microcalorimetry,
scanning electron microscopy
INTRODUCTION
Although many common infectious diseases can be initiated by
a single pathogen or virulence factor, others can be attributed
to a polymicrobial origin (Peters et al., 2012). Staphylococcus
aureus and Pseudomonas aeruginosa are commonly found in
mixed biofilm infections including chronically infected wounds,
indwelling medical devices, cystic fibrosis lung infection or
diabetic foot ulcers among others (Tande and Patel, 2014; Chew
et al., 2018). Usually, polymicrobial biofilm infections result in
worse clinical outcomes than the single infections caused by
either species (Serra et al., 2015; Limoli et al., 2016). Treatment
is often complicated due to the synergies of polymicrobial
biofilms on limiting the effectiveness of antibiotics (Wolcott et al.,
2013). Radlinski found that the interaction of S. aureus with
P. aeruginosa within a biofilm can alter S. aureus’ susceptibility
to different antibiotics (Radlinski et al., 2017), whereas other
authors also suggested a phenotypic change of S. aureus to a
small colony variant (SCV) in the presence of P. aeruginosa
(Chew et al., 2018), increasing its tolerance toward antibiotics
(Garcia et al., 2013).
The lack of effective therapies against polymicrobial biofilm
infections is a pressing need for the development of new
antimicrobial strategies. Bacteriophages (phages) have regained
interest as promising therapeutic option in fighting biofilm-
related infections due to their rapid bactericidal activity,
the self-amplification ability and potential biofilm degradative
properties (Harper et al., 2014). However, there are only limited
studies investigating the activity of phages against polymicrobial
biofilms (Sillankorva et al., 2010; Kay et al., 2011; Chhibber
et al., 2015; Oliveira et al., 2018; Melo et al., 2019) and just
recently Akturk et al. (2019) evaluated the simultaneous and
staggered administration of a P. aeruginosa-targeting monophage
and conventional antibiotics on S. aureus/P. aeruginosa dual-
species biofilms.
Pyophage (PYO) and Staphylococcal bacteriophage (Sb-1) are
two commercially available phage preparations manufactured by
Eliava Biopreparations, a company associated with the G. Eliava
Institute of Bacteriophages, Microbiology and Virology, Tbilisi,
Georgia. Sb-1 is a Staphylococcus-targeting phage preparation
containing the well characterized and fully sequenced Sb1
phage (Kvachadze et al., 2011), whereas PYO is composed by
a cocktail of phages targeting S. aureus, Streptococcus spp.,
Escherichia coli, P. aeruginosa, and Proteus species. An advantage
of using phages cocktails lies in a more broad antibacterial
spectrum of activity while minimizing the emergency of
bacterial resistance (Chan et al., 2013). Furthermore, phages
may encode extracellular polysaccharides (EPS) depolymerases
to facilitate their penetration within biofilms (Fernandes and
Sao-Jose, 2018). Indeed, in a previous study, we observed
the ability of Sb-1 to degrade the extracellular polysaccharide
component of S. aureus biofilm, which could have improved
synergism with antibiotics (Tkhilaishvili et al., 2018b). Thus,
in the present study, we investigated the effectiveness of
both phage preparations to enhance antibiotic activity in
eradicating S. aureus/P. aeruginosa dual-species biofilm. We
hypothesize that while PYO can target both bacterial species,
the addition of Sb-1 targeting not only S. aureus but also
the biofilm matrix, could help in completely eradicating the
dual-species biofilm when combined with an antibiotic. Mono-
and dual-species biofilms of S. aureus and P. aeruginosa were
reproducibly grown in porous glass beads and exposed to phages,
ciprofloxacin and their simultaneous or staggered combinations.
Furthermore, the morphological changes of biofilms induced by
each treatment condition were analyzed with scanning electron
microscopy (SEM).
MATERIALS AND METHODS
Bacterial Strains and Bacteriophages
Methicillin-resistant S. aureus (MRSA) ATCC 43300 and
P. aeruginosa ATCC 27853 strains were used in this study.
Bacteria were stored on a cryovial bead preservation system
(Microbank; Pro-Lab Diagnostics, ON, Canada) at−80 ◦C.
Phages Sb-1 and PYO were provided as 10 mL liquid ampoules
by the Eliava Institute for Bacteriophages, Microbiology and
Virology (Tbilisi, Georgia) and maintained at 4◦C. The phage
titer was determined by titration and expressed as PFU/mL.
A fixed titer of PYO corresponding to 105 PFU/mL for MRSA
and 104 PFU/mL for P. aeruginosa and of Sb-1 corresponding to
106 PFU/mL for MRSA were used for all tests.
Biofilm Formation Assay
In this study, we applied an optimized in vitro assay for
biofilm formation using porous sintered glass beads (diameter,
4 mm; pore size, 60 µm; porosity, 0.2 m2/g; ROBUVR, Hattert,
Germany) following the assay described by Zimmerli et al. (1994)
with some modifications.
Considering the findings from previous studies
predominantly showing an out-competition of S. aureus
growth by P. aeruginosa growth (Filkins et al., 2015; Woods et al.,
2019) bacterial inoculums in our study were prepared at a ratio
of 1 P. aeruginosa to 1000 MRSA bacterial cells.
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In order to allow mono- and dual-species biofilm formation
on the glass beads, a bacterial suspension of MRSA corresponding
to 5 × 106 CFU/mL and P. aeruginosa corresponding to
5 × 103 CFU/mL were incubated – alone or combined – in
Luria-Bertani broth (LB, Sigma-Aldrich, Steinheim, Germany)
in the presence of porous glass beads at 37◦C under static
conditions. After 3, 6, 12, or 24 h of incubation, beads were
washed three times in sterile 0.9% saline to remove non-adherent
bacteria suspended in the incubation medium. The number of
MRSA and P. aeruginosa bacteria adhering on the glass beads
was determined by sonication and colony counting (see section
“Sonication of Biofilms Formed on Porous Glass Beads and
Plating for Colony Counting”) in Mannitol salt agar (VWR
Chemicals, Leuven, Belgium) and Cetrimide selective agar media
(Sigma-Aldrich, Steinheim, Germany) respectively. The dual-
species biofilm formed in the beads was also visualized by SEM
(see section “SEM of Biofilms on Porous Glass Beads”).
Twenty-four hours old dual-species biofilms with a 1:1 ratio
of MRSA and P. aeruginosa bacterial cells on the beads were used
for anti-biofilm activity tests.
Sonication of Biofilms Formed on Porous
Glass Beads and Plating for Colony
Counting
The presence of attached cells to the glass beads was evaluated
by CFUs counting of sonicated beads as previously described
(Gonzalez Moreno et al., 2019). After biofilm formation, glass
beads were washed three times with 0.9% saline and introduced
in Eppendorf tubes containing 1 mL of sodium-phosphate buffer
solution (PBS). Samples were vortexed for 30 s and then subjected
to sonication in an ultrasound bath at 40 kHz and 0.2 W/cm2
(BactoSonic, BANDELIN electronic GmbH & Co., KG, Berlin,
Germany) for 1 minute, followed by additional 30 s vortexing.
10-fold serial dilutions of the sonication fluid were plated onto
the appropriate media and colonies were counted after 18–24 h
incubation at 37◦C and expressed as CFUs/mL.
SEM of Biofilms on Porous Glass Beads
For SEM imaging, biofilm was formed on porous glass beads as
described above. Afterward, all beads were washed in ddH2O
(dipping) to remove unbound bacteria and chemically fixed.
Subsequently, the samples were dehydrated in ethanol percent
series and then dried at the critical point. Samples were mounted
on aluminum stubs, coated with 20 nm layer of gold-palladium,
and then observed in the microscope (DSM 982 GEMINI,
Zeiss Oberkochen).
Antimicrobial Assay by Microcalorimetry
and Sonication/Colony Counting
An isothermal microcalorimeter (TAM III; TA Instruments,
New Castle, DE, United States) equipped with 48 channels
was used to determine the antimicrobial activity of either
antibiotic and/or phages against planktonic, mono- and dual-
species biofilms as previously reported (Butini et al., 2018;
Tkhilaishvili et al., 2018a,b). Briefly, MRSA or P. aeruginosa
planktonic cells (105 CFU/mL) were exposed to two-fold serial
dilutions of ciprofloxacin or to each phage preparation in LB,
and heat production was measured for 24 h. The minimum
heat inhibitory concentration (MHIC) was defined as the lowest
concentration of antimicrobial able to suppress the metabolic
heat production of planktonic bacteria.
Mono- and dual-species biofilms formed on porous glass
beads as previously described were rinsed (3×) with 0.9% saline
and exposed to fresh LB containing ciprofloxacin or phages.
After 24 h of incubation at 37◦C, beads were rinsed (3×)
with 0.9% saline and inserted in microcalorimetry ampoules
containing 3 mL of fresh LB and introduced into the calorimeter.
The viability of bacteria on the glass beads after the antibiotic
treatment was detected by measuring their heat production at
37◦C for 48 h. For samples where not heat production was
detected, the complete biofilm eradication was determined by
CFU counting of the sonicated beads after the microcalorimetric
assay. The minimum biofilm bactericidal concentration (MBBC)
was defined as the lowest concentration of antibiotic that strongly
reduced the viability of biofilm cells and led to the absence
of heat flow production from treated beads when incubated
during 48 h in fresh medium. The minimum biofilm eradicating
concentration (MBEC) was defined as the lowest concentration
of antibiotic required to kill all sessile cells resulting in the
appearance of no colony after plating sonication fluid (detection
limit: 20 CFU/mL) (Gonzalez Moreno et al., 2019; Wang
et al., 2019). All experiments were performed in triplicate and
repeated three times.
To evaluate the antimicrobial effect of antibiotic/phage
combinations, two different approaches were carried out: (i)
simultaneous exposure of biofilms to PYO or PYO+Sb-1 and
sub-inhibitory concentrations of ciprofloxacin for 24 h; (ii)
staggered exposure of biofilms to PYO or PYO+Sb-1 phages
for 3, 6, 12, or 24 h followed by a 24 h-exposure to sub-
inhibitory concentrations of ciprofloxacin. The viability of
bacteria on the glass beads after the antibiotic/phage treatment
was determined by both, calorimetry and sonication/colony-
counting as previously mentioned.
For each tested condition throughout all experiments, grown
biofilms were rinsed with 0.9% saline prior exposure to fresh LB
containing the respective antimicrobials.
Microcalorimetry data was evaluated using the manufacturer’s
software (TAM Assistant; TA Instruments, New Castle, DE,
United States) and figures were plotted using GraphPad Prism
6.01 (GraphPad Software, La Jolla, CA, United States).
RESULTS
Formation of Mono- and Dual-Species
Biofilm
MRSA and P. aeruginosa were used to grow mono- and dual-
species biofilms. The evaluation of the bacteria adhered to the
beads over time showed a considerably higher concentration
of MRSA cells at 3 and 6 h of incubation in dual-species
biofilms compared to P. aeruginosa cells (Figure 1A,B), whereas
at 12 h of incubation the concentration of P. aeruginosa
increased substantially (Figure1C) and at 24 h of incubation
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FIGURE 1 | Distribution pattern of bacterial populations over the time. Number of viable cells (in log10 CFU/mL) of P. aeruginosa and MRSA on mono- and
dual-species biofilms formed after 3 h (A), 6 h (B), 12 h (C) and 24 h (D). Data are reported as CFU/mL mean ± standard deviation of at least three independent
experiments. Figure 2 | Dual-species biofilm formed by MRSA (ATCC 43300) and P. aeruginosa (ATCC 27853) on porous glass beads after 24 h of incubation.
Image (B) is a close-up from (A). Numbers 1 and 2 indicate a MRSA bacterium and a P. aeruginosa bacterium, respectively, whereas three and four point out a water
channel and the extracellular polymeric matrix of the biofilm correspondingly.
the concentration of P. aeruginosa showed values comparable to
those from MRSA (Figure 1D).
Results showed approximately a 1:1 ratio of MRSA
(9.7 × 105 CFU/mL) and P. aeruginosa (3.7 × 106 CFU/mL)
bacterial cells on the beads of dual-species biofilms after 24 h
of incubation. MRSA and P. aeruginosa mono-species biofilms
presented bacterial concentrations comparable to those observed
on the dual-species biofilm after 24 h of incubation.
The SEM analysis of 24 h-old dual-species biofilms showed the
capability of MRSA and P. aeruginosa to adhere and form an even
mixed biofilm on the porous glass beads (Figure 2).
Antimicrobial Activity of Ciprofloxacin or
Phages Against Planktonic, Mono- and
Dual-Species Biofilms
The antimicrobial susceptibility of planktonic cells
(Figure 3) or mono- and dual-species biofilms (Figure 4)
to ciprofloxacin or to phages was determined by
isothermal microcalorimetry.
The calorimetry analysis for planktonic bacteria showed that
MRSA and P. aeruginosa were susceptible to ciprofloxacin with
MHIC values of 0.5 and 0.25 mg/L, respectively. The exposure
of MRSA to PYO revealed a high reduction of heat production
compared to the growth control, a complete inhibition of the heat
production could be observed in the case of P. aeruginosa. The
combination of PYO+Sb-1 showed complete growth inhibition
against both bacterial species.
Mono-species biofilms from both strains were susceptible
to considerable high concentrations of ciprofloxacin
(512 mg/L for MRSA and 256 mg/L for P. aeruginosa),
whereas the antibiotic was not able to completely inhibit
the heat flow production of the dual-species biofilm when
tested up to 512 mg/L.
The exposure of MRSA biofilm to PYO revealed a drastic
reduction of the heat production compared to the growth control,
and with the addition of Sb-1, a complete inhibition of the
biofilm could be achieved. On the contrary, neither PYO nor
PYO+Sb1 showed a noteworthy anti-biofilm activity against
P. aeruginosa biofilm, whereas on dual-species biofilm, a delay
on the heat production could be observed on treated samples
with PYO, indicating a moderate anti-biofilm activity, which was
seen improved by the addition of Sb1 but with no complete
inhibition of the biofilm.
Biofilm-Eradicating Activity of Phage
Preparations
In order to evaluate the biofilm-eradicating activity of the
two phage preparations, mono- and dual-species biofilms were
exposed to PYO or to PYO+Sb-1 for 24 h and then, viable
bacteria attached to the beads were detected by colony counting
after bead sonication and plating of the sonication fluids.
A higher reduction of MRSA viable bacteria after exposure to
PYO could be observed (Figure 5A) compared to P. aeruginosa
biofilm, where no considerable bacterial reduction was
determined (Figure 5B). Moreover, a complete eradication
of MRSA biofilm was observed after exposure to PYO+Sb-1,
although this phage combination did not improve the killing of
P. aeruginosa biofilm compared to PYO alone.
Regarding the phage activity against dual-species biofilm
(Figure 5C), a reduction of more than 2 log10 of MRSA and
around 1 log10 of P. aeruginosa cells was observed after exposure
to PYO in comparison to the growth control. The combination
of PYO+Sb-1 showed a complete eradication of MRSA cells
on the dual-species biofilm, whereas no substantial reduction of
P. aeruginosa cells was observed.
Anti-biofilm Activity of Ciprofloxacin in
Combination With Phages Against
Dual-Species Biofilm
Simultaneous exposure of sub-inhibitory concentrations of
ciprofloxacin combined with PYO or PYO+Sb-1 revealed
a remarkable delay and reduction of heat flow production
compared to the heat flow produced by the growth
control (Figure 6).
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FIGURE 2 | SEM analysis of dual-species biofilm formed by MRSA (ATCC 43300) and P. aeruginosa (ATCC 27853) on porous glass beads after 24h of incubation.
Image (b) is a close-up from (a). Numbers 1 and 2 indicate a MRSA bacterium and a P. aeruginosa bacterium respectively, whereas 3 and 4 point out a water
channel and the extracellular polymeric matrix of the biofilm correspondingly.
FIGURE 3 | Microcalorimetry analysis of planktonic MRSA ATCC 43300 (A) and P. aeruginosa ATCC 27853 (B) cells treated with two-fold increasing concentrations
of ciprofloxacin (left column, numbers represent concentrations in mg/L of antibiotic) or with phages (right column). A circled value represents the MHIC, defined as
the lowest concentration of antimicrobial able to suppress the metabolic heat production of planktonic bacteria. GC, growth control (dashed line); NC, negative
control. Data of a representative experiment are reported.
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FIGURE 4 | Microcalorimetry analysis of (A,B) mono- and (C) dual-species MRSA (ATCC 43300) and P. aeruginosa (ATCC 27853) biofilms treated with two-fold
increasing concentrations of ciprofloxacin (left column, numbers represent concentrations in mg/L of antibiotic) or with phages (right column). Each curve shows the
heat produced by viable bacteria present in the biofilm after 24 h of antibiotic or phage treatment. A circled value represents the MBEC, defined as the lowest
concentration of antibiotic that strongly reduced the viability of biofilm cells leading to the absence of heat flow production from treated beads when incubated during
48 h in fresh medium and no colonies after sonication and plating. GC, growth control (dashed line); NC, negative control. Data of a representative experiment are
reported.
The combination of PYO and ciprofloxacin revealed a
decrease of over 90% in heat flow production of samples treated
with 16–64 mg/L of antibiotic compared to the growth control,
whereas in the case of combining PYO+Sb-1 and ciprofloxacin,
a concentration of antibiotic as low as 4 mg/L was already able
to reduce over a 90% of the heat flow production if compared
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FIGURE 5 | Effect of PYO and Sb-1 phage preparations on viability of biofilm-embedded mono and mix bacteria populations. S. aureus/P. aeruginosa mono- (A,B)
and dual-species (C) biofilms formed on porous glass beads were exposed to phages. Data are reported as log10 CFUs/mL mean ± standard deviation of at least
three independent experiments. Percent of cell reduction of treated samples compared to untreated samples was calculated as: percent reduction = [(A–B)/A]×100,
where A is the mean number of viable bacteria of the growth control and B is the mean number of viable bacteria after exposure to PYO or PYO+Sb-1.
FIGURE 6 | Evaluation of MRSA ATCC 43300/P. aeruginosa ATCC 27853 dual-species biofilm viability after simultaneous exposure during 24 h to ciprofloxacin at
increasing doses (0.5–64 mg/L) plus (A) PYO or (B) PYO+Sb-1 monitored by microcalorimetry. Numbers represent antibiotic concentrations (in mg/L). GC, growth
control (dashed line); NC, negative control.
to that one measured for the growth control. Still, no complete
biofilm eradication was observed with any of the both tested
treatment combinations.
Paradoxically, low concentrations of ciprofloxacin (0.5–
1 mg/L) in combination with phages showed a higher
delay/decrease in heat flow production, correlating with a lower
loading of bacterial cells in the beads, if compared to the heat flow
curves observed after exposure to concentrations of ciprofloxacin
ranging from 2 to 8 mg/L, in combination with phages.
On the other hand, a staggered exposure of phage and
antibiotic against dual-species biofilms was evaluated by
microcalorimetry. The obtained results are depicted in Figure 7.
Dual-species biofilms were first exposed to phages at different
incubation times (3, 6, 12, and 24 h) and then to sub-inhibitory
concentrations of ciprofloxacin for 24 h. After calorimetry, the
complete eradication of the biofilm was further investigated by
sonication and colony counting of those samples showing no heat
flow production after 48 h of incubation.
Results showed the highest anti-biofilm activity when the
antibiotic was added after 12 h of pre-exposure to either PYO or
PYO+Sb-1, where a complete eradication of the biofilm could
be achieved at MBEC of ciprofloxacin of 2 mg/L (Figure 7E)
and 1 mg/L (Figure 7F) respectively. Similarly, relatively low
MBEC values were also obtained when ciprofloxacin was added
after 6 h of biofilm pre-treatment with PYO (MBEC = 4 mg/L)
(Figure 7C) or PYO+Sb-1 (MBEC = 1 mg/L) (Figure 7D).
On the contrary, when biofilms were incubated for 3 or 24 h
with phages prior addition of ciprofloxacin, higher MBEC values
ranging from 16 to 64 mg/L were observed. Generally, the
PYO+Sb-1/ciprofloxacin combination exhibited MBEC values
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FIGURE 7 | Evaluation of MRSA ATCC 43300/P. aeruginosa ATCC 27853 dual-species biofilm viability after staggered exposure to phages and ciprofloxacin
monitored by microcalorimetry. Each curve shows the heat produced by viable bacteria present in biofilms pretreated for 3 h (A,B), 6 h (C,D), 12 h (E,F) and 24 h
(G,H) with PYO (graphs on the left) or PYO+Sb-1 (graphs on the right) followed by exposure to ciprofloxacin at increasing doses (0.5–64 mg/L) for 24 h. Numbers
above curves represent antibiotic concentrations (in mg/L). Circled values represents the MBEC, defined as the lowest concentration of antibiotic that strongly
reduced the viability of biofilm cells leading to the absence of heat flow production from treated beads when incubated during 48 h in fresh medium and no colonies
after sonication and plating. GC, growth control (dashed line); NC, negative control.
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FIGURE 8 | SEM analysis of S. aureus/P. aeruginosa dual-species biofilms grown on porous glass beads for 24 h without treatment (a) and after exposure to 24 h
monotherapy with (b) ciprofloxacin (1 mg/L); (c) PYO; or (d) pyo+sb-1.
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FIGURE 9 | SEM analysis of S. aureus/P. aeruginosa dual-species biofilm grown on porous glass beads for 24 h and treated with a combinatorial therapy of (a)
simultaneous exposure to PYO and ciprofloxacin (1 mg/L, 24 h); (b) staggered exposure to PYO (12 h) followed by ciprofloxacin (1 mg/L, 24 h); (c) simultaneous
exposure to PYO+Sb-1 and ciprofloxacin (1 mg/L, 24 h); or (d) staggered exposure to PYO+Sb-1 (12 h) followed by ciprofloxacin (1 mg/L, 24 h).
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2–4 times lower than the PYO/ciprofloxacin combination at all
the tested incubation times.
SEM Analysis
In order to further confirm our findings, dual-species biofilm
after exposure to either antimicrobials alone or in combinations
were visualized by SEM (Figures 8, 9). The microscopy
analysis revealed comparable outcomes to those obtained by
microcalorimetry and sonication/colony-counting.
No presence of bacteria on the beads was observed after
biofilm exposure to phages for 12 h followed by 24 h of exposure
to 1 mg/L ciprofloxacin (Figure 9, images B,D). Ciprofloxacin
alone at that same concentration (1 mg/L) showed abundant
biofilm formation on the bead (Figure 8, image B), indicating no
anti-biofilm activity at that concentration.
Different outcomes were observed when biofilms were
exposed to PYO+Sb-1 (Figure 8D), were a relatively lower
abundance of biofilm and especially of MRSA bacterium cells
could be visualized, compared to PYO alone (Figure 8C). Finally,
the beads exposed to simultaneous incubation with phages and
ciprofloxacin (Figure 9, images A,C) showed a sharp decrease of
biofilm without complete eradication.
DISCUSSION
S. aureus and P. aeruginosa are two bacterial pathogens
commonly isolated in mixed-species biofilm infections
(Hotterbeekx et al., 2017). A vast number of studies suggest
that, when both bacterial species interact to form biofilm,
S. aureus is predominantly outcompeted by P. aeruginosa
(Machan et al., 1991; Mashburn et al., 2005; Filkins et al., 2015;
Woods et al., 2019). However, other studies found that both
species may benefit each other during the infection and keep
a stable co-existence (Pastar et al., 2013; DeLeon et al., 2014;
Woods et al., 2019). In our study, we observed a similar trend,
where the growth of S. aureus biofilm was outcompeted by
P. aeruginosa during a period of 24 h in vitro, despite the higher
initial inoculum size of S. aureus in relation to P. aeruginosa,
and both species could form an even mixed biofilm after 24 h of
co-incubation, as shown by colony-counts and SEM.
It has been shown that S. aureus/P. aeruginosa coinfections
result in enhanced virulence and resistance to antibiotics
(DeLeon et al., 2014). Our results also revealed that a higher
concentration of ciprofloxacin was necessary to inhibit the
growth of dual-species biofilms when compared with mono-
species biofilms. The MBEC values obtained in all cases are too
high to be reached in the clinical practice (Kontou et al., 2011;
Thabit et al., 2019). In this scenario, bacteriophages appear to
be an alternative strategy to treat biofilm-forming infections.
Over the past few years, numerous studies have been carried out
investigating the effectiveness of phages against mono- and dual-
species biofilm (Sillankorva et al., 2010; Chhibber et al., 2015;
Gutierrez et al., 2015; Gonzalez et al., 2017; Melo et al., 2019).
Many of these studies pointed to a notable dependency between
the phages and the bacterial species involved on the biofilm for
the efficacy of the phage treatment. Indeed, it is generally accepted
that the efficacy of phages against bacteria is influenced by several
factors, among others, the host specificity, the treatment method,
environmental conditions or accessibility to target bacteria (Ly-
Chatain, 2014). The impact of host specificity for the therapeutic
use of phages is also under debate (Ross et al., 2016; Hyman,
2019). Thus, in contrast to other studies where they make use
of self-isolated phages targeting the bacterial strains under study,
for our study we chose to investigate commercially available
phage preparations with the potential to a more straightforward
implementation in a clinical setting.
Our results showed that, even though planktonic cells from
both tested species were susceptible to the PYO phage-cocktail,
when tested against biofilms, only MRSA showed a substantial
reduction on bacterial viability, especially as mono-species
biofilm, whereas a lower efficacy was observed against dual-
species biofilms. A possible explanation for this might be a limited
phage penetration within the biofilm, what could be improved
by the addition of the MRSA targeting and matrix-degrading
Sb-1 phage. The combination of PYO+Sb-1 showed a major
eradication of MRSA cells on the dual-species biofilm, as seen
also by SEM, however, no substantial reduction of P. aeruginosa
cells was observed. A possible additional effect on the reduction
of MRSA could be due to the natural competition between the
two species as mentioned above.
To enhance the effect of phages, the combined exposure
with an antibiotic was assessed. Phage- antibiotic synergy is the
result of combining sub-inhibitory concentrations of antibiotics
with phages to foster phage productivity and thus phage-
mediated bacterial decline (Tagliaferri et al., 2019). Previous
studies have shown the benefit of the staggered application when
combining antibiotics and phages, while a simultaneous exposure
could result in hindering their anti-biofilm efficacy, possibly
due to antagonistic modes of action (Chaudhry et al., 2017;
Kumaran et al., 2018; Akturk et al., 2019). Indeed, when we
analyzed by calorimetry the exposure of dual-species biofilms
to ciprofloxacin and PYO or PYO+Sb-1 simultaneously, we
observed a paradoxical effect, where lower concentrations of
ciprofloxacin in combination with phages showed a higher
delay/decrease in heat flow production compared to higher
antibiotic concentrations. We assume that the mode of action of
ciprofloxacin inhibiting bacterial DNA replication might hamper
the phage amplification (replication) (Constantinou et al., 1986).
Therefore, lower doses of ciprofloxacin could have a minor
interference with phage replication or could not reduce the
concentration of bacteria to levels below which phages can
replicate, if compared to higher antibiotic doses (Levin et al.,
1977). This counterproductive effect could be perhaps prevented
by the use of antibiotics with modes of action that do not
compete with the viral amplification, or also, by exposing
bacteria in a staggered rather than a simultaneous manner
to phages and antibiotics. As seen in our study, a complete
eradication of dual-species biofilm could be only achieved by
staggered administration of phages followed by a sub-inhibitory
concentration of ciprofloxacin.
As recently stated by Tagliaferri et al. (2019), synergistic
interactions between antimicrobial agents may be strongly
dependent on the treatment conditions such as dosage,
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frequency, time points and order of administration. Hence, we
were interested on determining the optimal time point for the
staggered administration of phages and the antibiotic. Our results
showed that the highest anti-biofilm activity could be reached
when ciprofloxacin was added after 6 or 12 h of pre-exposure to
PYO+Sb-1. SEM analysis also revealed the absence of adherent
bacterial cells on the glass beads.
Differently, pre-incubation of dual-species biofilms with
phages for 3 or 24 h prior addition of ciprofloxacin exhibited
higher MBEC values, confirming that, not only dosage but also
an optimal time of antimicrobial exposure is crucial in the
implementation of the combined therapies.
In conclusion, this work provides valuable original data
on the combinatorial use of phage and antibiotic against
S. aureus/P.aeruginosa dual-species biofilm that might bring
new insights into the potential application of such a treatment
to combat polymicrobial infections. Monotherapy with
ciprofloxacin revealed drug concentrations to eradicate biofilm
(MBEC >512 mg/L) much superior to the ones reachable in
clinical practice, whereas a combinatorial treatment by staggered
administration of phages and ciprofloxacin strongly reduced
the MBEC of ciprofloxacin to a dose (MBEC = 1 mg/L)
achievable by intravenous or oral antibiotic administration
(Kontou et al., 2011; Thabit et al., 2019). Moreover, by the
use of commercially available phage preparation in this study,
we were able to show the effectiveness of these preparations
against bacterial strains that have not been used specifically for
their isolation.
Over the last years, bacteriophages have been extensively
studied as therapeutic agents alone or in conjunction with other
therapeutics. In vivo models (Tagliaferri et al., 2019) and a few
clinical trials (Merabishvili et al., 2017; Furfaro et al., 2018; Jault
et al., 2019) have demonstrated effectiveness of phage treatment
against P. aeruginosa and S. aureus infections, without any
reported adverse effects. However, little has been published about
polymicrobial biofilm infections. Although these infections are
less common, their treatment presents a major challenge. Hence,
further preclinical and clinical studies are essential to support
the development of phage/antibiotic combination therapy for
polymicrobial infections.
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